- Home
- IBTA vs BHVN Comparison
IBTA vs BHVN Comparison
Compare IBTA & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | BHVN |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.8M | 1.1B |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IBTA | BHVN |
|---|---|---|
| Price | $21.46 | $11.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $37.38 | $29.79 |
| AVG Volume (30 Days) | 465.4K | ★ 3.5M |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 395.09 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $352,243,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,219.74 |
| P/E Ratio | $8.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.40 | $7.48 |
| 52 Week High | $76.00 | $44.28 |
Technical Indicators
Market Signals| Indicator | IBTA | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 57.02 |
| Support Level | $22.19 | $8.29 |
| Resistance Level | $24.40 | $11.71 |
| Average True Range (ATR) | 0.88 | 0.72 |
| MACD | 0.04 | 0.47 |
| Stochastic Oscillator | 2.56 | 95.32 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.